CareRx Corporation
TSX:CRRX.TOMedical - Care Facilities
+$0.02 today
- Market cap
- $203.06M
- Beta
- 0.62
- P/E (TTM)
- 7.4
- EPS (TTM)
- $0.43
- Dividend yield
- 1.88%
Volume 0.01M
Average 0.04M
CRRX.TO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
CareRx CorporationTSX: CRRX.TO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was CA$0, compared with CA$0 a year earlier. Trailing-twelve-month research & development was CA$0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
CAD · from the income statement
- Latest · FY2025
- 0 CAD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How CRRX.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.0% of revenue for CRRX.TO, versus a peer median of 0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
PRN.TOProfound Medical Corp. | LTM Mar 2026 | $20.97M USD | +17.5% | +12.6% | 111.8% |
| LTM Apr 2026 | CA$1.62M CAD | -72.8% | -7.7% | — | |
| LTM Mar 2026 | CA$267K CAD | +62.8% | — | 0.2% | |
| LTM Mar 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CRRX.TO) | — | +17.5% | +2.4% | 0.1% | |
Competitors are the stored peer set for CRRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 262.63M | 381.73M | 370.75M | 366.71M | 370.24M |
| Cost of Revenue | 187.35M | 271.79M | 286.02M | 258.65M | 277.61M |
| Gross Profit | 75.28M | 109.93M | 84.72M | 108.06M | 92.63M |
| Gross Margin | 28.7% | 28.8% | 22.9% | 29.5% | 25.0% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 70.52M | 102.55M | 77.5M | 32.75M | 34.23M |
| Operating Expenses | 70.47M | 82.24M | 100.03M | 103.54M | 80.75M |
| Depreciation & Amortization | 15.39M | 20.07M | 19.98M | 19.19M | 18.33M |
| EBITDA | 9.01M | (610K) | 24.65M | 23.9M | 30.22M |
| EBITDA Margin | 3.4% | -0.2% | 6.6% | 6.5% | 8.2% |
| Operating Income | (3.31M) | (21.94M) | 4.67M | 4.53M | 11.88M |
| Operating Margin | -1.3% | -5.7% | 1.3% | 1.2% | 3.2% |
| Interest Income | 58K | 278K | 1.26M | 63K | 161K |
| Interest Expense | 17.35M | 15.22M | 14.27M | 9.18M | 6.84M |
| Other Income / Expenses | (20.43M) | (13.95M) | (14.27M) | (8.99M) | (8.53M) |
| Income Before Tax | (23.74M) | (35.9M) | (9.6M) | (4.47M) | 3.35M |
| Pre-Tax Margin | -9.0% | -9.4% | -2.6% | -1.2% | 0.9% |
| Income Tax Expense | (1.01M) | (1.54M) | (4.19M) | 32K | (22.77M) |
| Net Income | (22.73M) | (34.35M) | (5.41M) | (4.5M) | 26.13M |
| Net Margin | -8.7% | -9.0% | -1.5% | -1.2% | 7.1% |
| EPS (Basic) | (0.65) | (0.72) | (0.09) | (0.07) | 0.42 |
| EPS (Diluted) | (0.65) | (0.72) | (0.09) | (0.07) | 0.41 |
| Weighted Avg Shares | 34.86M | 47.6M | 57.35M | 60.25M | 62.73M |
| Weighted Avg Shares (Diluted) | 34.86M | 47.6M | 57.35M | 60.25M | 64.49M |
CareRx Corporation
TSX:CRRX.TO
Intrinsic Alpha fair value
Locked
Current Price
$3.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.